Advertisement
Advertisement
Trending on OncLive
1
A global, randomized, double-blinded, Phase 3 trial of vorasidenib vs placebo in patients with grade 2 glioma with an IDH1/2 mutation (INDIGO): updated efficacy and safety
2
Mirvetuximab Soravtansine/Carboplatin Improves ORR But Fails to Extend PFS in FRα-High Recurrent Ovarian Cancer
3
OncLive Weekly News Quiz (6/19/2026): Did You Catch This Week's Updates in LBCL and Breast Cancer?
4
Mocertatug Rezetecan Drives Rapid, Deep Responses in Platinum-Resistant Ovarian and Recurrent/Advanced Endometrial Cancer
5